Advance Your Neurodegenerative Clinical Trial With Confidence
Navigate the complexities of neurodegenerative research with a trusted partner that understands the urgency of developing effective treatments.
Over the past five years, we’ve conducted Phase I-IV studies across more than 15 rare and non-rare indications, including:
Alzheimer’s
Disease
Parkinson’s Disease
Multiple
Sclerosis
Frontotemporal Dementia
Amyotrophic Lateral Sclerosis
Founded in neuroscience, committed to personalized experiences.
years average tenure of
neuroscience project managers.
marketing authorizations for
which Worldwide conducted
the pivotal studies
Patients with neurodegenerative disorders become increasingly reliant on a care partner for decision-making and daily activities. As a result, caregivers play a crucial role in neurodegenerative disease studies, making it essential to consider the caregiver perspective to support trial participation.
Project Teams Experienced in Dementias
With expert advisors offering tailored medical, scientific, and operational experience in Alzheimer’s disease and other dementias, your study has access to neuropsychologists and neuroimaging experts who have contributed to the development of every drug class applicable to dementia diseases in the past 30 years. Our professionals also participate in the Alzheimer’s Disease Assessment Scale (ADAS) development of a Cognitive Task Force for large trials to help meet enrollment goals faster, improve patient lives, and enhance site, PI, & KOL interactions.
Local Expertise, Global Reach
Founded in neuroscience, Worldwide has spent the past 40+ years building a global network of leading investigators and consultants. Located in more than 60 countries, we’re highly experienced in navigating regional standards of care and have established local relationships with regulatory agencies, KOLs, and sites around the globe to help drive study success. Our teams have also identified the best locations for neuroscience imaging, CSF & biomarkers studies, and dementia sub-studies.
In-House Clincal Assessment Technologies
Worldwide is one of the few full-service CROs that offers in-house clinical assessment technology (CAT) offerings. Our CAT team provides our sponsors with seamless assessment and endpoint quality support, which helps reduce placebo response, increase financial and operational efficiencies, deliver faster and more integrated study start-ups, and more. With extensively trained experts, we help unite patient experience and practical designs through rigorous data to position your study for success.
Studies
Unique Sites
Participants
Countries
Meet Our Team
Our dedicated, global neuroscience team leverages 40+ years of expertise to ensure your study is designed for success from the start.
Natalia Drosopoulou, PhD
Senior Vice President, Project Management, Neuroscience
Tom Babic, MD, PhD
Vice President, Scientific Solutions, Neuroscience
Christine Moore, PhD
Vice President, Neuroscience, Scientific Solutions
Tamara Ast, PhD
Executive Vice President, Global Project Delivery
On your next neurodegenerative disease clinical trial, work with a CRO as dedicated to its success as you are.
Please submit your information, and we’ll be in touch shortly.